CTGF is a therapeutic target for metastatic melanoma
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Metastatic melanoma remains a devastating disease with a 5-year survival rate of less than five percent. Despite recent advances in targeted therapies for melanoma, only a small percentage of melanoma patients experience durable remissions. Therefore, it is critical to identify new therapies for the treatment of advanced melanoma. Here, we define connective tissue growth factor (CTGF) as a therapeutic target for metastatic melanoma. Clinically, CTGF expression correlates with tumor progression and is strongly induced by hypoxia through HIF-1 and HIF-2-dependent mechanisms. Genetic inhibition of CTGF in human melanoma cells is sufficient to significantly reduce orthotopic tumor growth, as well as metastatic tumor growth in the lung of severe combined immunodeficient (SCID) mice. Mechanistically, inhibition of CTGF decreased invasion and migration associated with reduced matrix metalloproteinase-9 expression. Most importantly, the anti-CTGF antibody, FG-3019, had a profound inhibitory effect on the progression of established metastatic melanoma. These results offer the first preclinical validation of anti-CTGF therapy for the treatment of advanced melanoma and underscore the importance of tumor hypoxia in melanoma progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134
The role of hypoxia-inducible factors in tumorigenesis
Rankin, E. B., & Giaccia, A. J. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.21 · Cited by 806
Self-citation
Cited by
Poltavets, V., Kochetkova, M., Pitson, S. M., & Samuel, M. S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00431 · Cited by 377
Connective tissue growth factor (CTGF) from basics to clinics
Ramazani, Y., Knops, N., Elmonem, M. A., Nguyen, T. Q., Arcolino, F. O., van den Heuvel, L., Levtchenko, E., Kuypers, D., & Goldschmeding, R. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.007 · Cited by 329
Tsai, H.-C., Su, H.-L., Huang, C.-Y., Fong, Y.-C., Hsu, C.-J., & Tang, C.-H. (2014) · Oncotarget · doi:10.18632/oncotarget.1998 · Cited by 78
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis
Sgalla, G., Franciosa, C., Simonetti, J., & Richeldi, L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1773790 · Cited by 59
Ohara, Y., Chew, S. H., Misawa, N., Wang, S., Somiya, D., Nakamura, K., Kajiyama, H., Kikkawa, F., Tsuyuki, Y., Jiang, L., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24892 · Cited by 44
“FG-3019 has shown inhibitory activity in preclinical animal models of pancreatic cancer, pre-B cell acute lymphoblastic leukemia and melanoma [23-25 , 39 ].”
Metadata
- Authors
- Finger, E. C., Cheng, C.-F., Williams, T. R., Rankin, E. B., Bedogni, B., Tachiki, L., Spong, S., Giaccia, A. J., & Powell, M. B.
- Venue
- Oncogene
- Published
- 2013-02-25
- Volume
- 33
- Issue
- 9
- Pages
- 1093-1100
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2036158954
- Cited by
- 78
- References
- 3
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CTGF is a therapeutic target for metastatic melanoma. https://app.cochat.ai/papers/10.1038/onc.2013.47
- The paper
- Finger, E. C., Cheng, C.-F., Williams, T. R., Rankin, E. B., Bedogni, B., Tachiki, L., Spong, S., Giaccia, A. J., & Powell, M. B. (2014). CTGF is a therapeutic target for metastatic melanoma. Oncogene. https://doi.org/10.1038/onc.2013.47
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.